Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Basic study about the effect of neoadjuvant chemotherapy on the biomarker profiles Additional study of phase II trial of neoadjuvant chemotherapy for unresectable liver metastasis of colorectal cancer

ABSTRACT: Primary outcome(s): Changes of biomarker molecules on the genetic and protein levels

DISEASE(S): Colorectal Cancer With Unresectable Liver Metastasis

PROVIDER: 2622691 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Comprehensive evaluation of the relationship between biomarker profiles and neoadjuvant chemotherapy outcomes for breast cancer patients

Project description: Not available

| S-EPMC10953119 | biostudies-literature

Alterations of biomarker profiles after neoadjuvant chemotherapy in breast cancer: tumor heterogeneity should be taken into consideration.

Project description: Not available

| S-EPMC4742218 | biostudies-literature

Response prediction to neoadjuvant chemotherapy

Project description:We investigated whether we could identify gene expression profiles in initial core biopsies of breast cancer samples that would permit to a) predict a clinically meaningful response to Epi/Doc in terms of tumor size reduction, b) predict a profound reduction in intratumoral Ki67 protein expression, and c) predict an in vitro response to Epi/Doc in the ATP-TCA. 22 Samples from breast cancer patients with corresponding treatment response indicators

2012-10-26 | E-GEOD-29561 | biostudies-arrayexpress

Basic analysis of new evaluation method in neoadjuvant chemotherapy (Additional study of phase II trial of neoadjuvant chemotherapy for unresectable liver metastasis of colorectal cancer)

Project description:Primary outcome(s): To study correlation with rate of tumor shrinkage by CT, rate of tumor maker decrease and CTC changes

| 2622416 | ecrin-mdr-crc

Treatment strategies for patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy: interval debulking surgery or additional chemotherapy?

Project description: Not available

| S-EPMC6658596 | biostudies-literature

Response prediction to neoadjuvant chemotherapy

2012-10-26 | GSE29561 | GEO

Detection of Chemotherapy-Resistant Pancreatic Cancer Using a Glycan Biomarker

Project description:A subset of pancreatic ductal adenocarcinomas (PDACs) is highly resistant to systemic chemotherapy, but no markers are available in clinical settings to identify this subset. We found that chemotherapy-resistant PDACs, but not chemotherapy-sensitive PDACs, express a glycan biomarker called sTRA. We confirmed the use of this marker to identify treatment-resistant PDAC in multiple systems: sets of 24 cell lines, 27 organoids, and isogenic cell lines; gene-expression signatures in primary tumors; tissue microarrays containing primary tumors; and blood plasma from cohorts of human subjects. These findings establish the use of tissue or plasma assays to identify the PDACs that are resistant to chemotherapy, which could improve the precision of systemic treatments and facilitate biomarker-guided trials targeting resistant PDAC.

2021-04-13 | GSE146722 | GEO

Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism.

Project description: Not available

| S-EPMC5592784 | biostudies-literature

FZR1 as a novel biomarker for breast cancer neoadjuvant chemotherapy prediction.

Project description: Not available

| S-EPMC7519164 | biostudies-literature

Tumors with neoadjuvant chemotherapy

Project description:Using whole genome mRNA expression profiling of primary human tumors and unsupervised hierarchical cluster analyses, 3 novel molecular subsets (basal, luminal and p53-like subsets) of muscle-invasive bladder cancer (MIBC) were identified. 23 MVAC treated samples were used for the validation of three MIBC subsets MVAC cohort consisted of 23 FFPE pretreatment tumors (TURs) from a Phase III clinical trial were used to validate 3 molecular subsets including basal, luminal and p53-like subsets We used Illumina cDNA-mediated Annealing, Selection, Extension, and Ligation (DASL) assay that is specifically designed for the gene expression of RNA that is extracted from FFPE.

2014-02-10 | E-GEOD-52219 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data